^
    2d
    NAHL: Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=9, Active, not recruiting, University of Utah | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Opdivo (nivolumab) • Niktimvo (axatilimab-csfr)
    5d
    Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel) (clinicaltrials.gov)
    P1, N=24, Recruiting, Deciphera Pharmaceuticals, LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Romvimza (vimseltinib)
    5d
    A Phase I Clinical Study of AK150 in Advanced Malignant Solid Tumor (clinicaltrials.gov)
    P1, N=96, Not yet recruiting, Akeso
    New P1 trial
    10d
    INCA34176-254: A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease (clinicaltrials.gov)
    P2, N=120, Recruiting, Incyte Corporation | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Jakafi (ruxolitinib) • prednisone • Niktimvo (axatilimab-csfr)
    11d
    Integrative bioinformatics and molecular simulations identify HMGB3 as a key immune modulator in triple negative breast cancer. (PubMed, Discov Oncol)
    This work identifies HMGB3 as a promising immunotherapeutic target in the MLIA subtype of TNBC and highlights Pimicotinib, CID17584963, and CID1763476 as potential HMGB3 inhibitors for drug repurposing strategies.
    Journal
    |
    NEAT1 (Nuclear Paraspeckle Assembly Transcript 1) • MIR214 (MicroRNA 214)
    |
    pimicotinib (ABSK021)
    13d
    Targeting GPR34 in damage-associated macrophages enhances anti-tumor immunity and the efficacy of Surufatinib in pancreatic cancer. (PubMed, Signal Transduct Target Ther)
    Combining a GPR34 antagonist with chemotherapy and surufatinib significantly enhanced anti-tumor responses in preclinical models. These findings identify GPR34 as a promising immune therapeutic target.
    Journal
    |
    CD8 (cluster of differentiation 8) • CSF1R (Colony stimulating factor 1 receptor)
    |
    Sulanda (surufatinib)
    18d
    Efficacy and Safety of Surufatinib in Treating Pituitary Neuroendocrine Tumors: A Single-Center, Single-Arm, Exploratory Study (ChiCTR2600120740)
    P=N/A, N=40, Huashan Hospital, Fudan University; Huashan Hospital, Fudan University
    New trial
    |
    Sulanda (surufatinib)
    20d
    Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel) (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Deciphera Pharmaceuticals, LLC
    New P1 trial
    |
    Romvimza (vimseltinib)
    20d
    ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation (clinicaltrials.gov)
    P2, N=34, Not yet recruiting, Stephen Shiao | Trial completion date: Dec 2032 --> Jul 2033 | Initiation date: Sep 2025 --> Jun 2026 | Trial primary completion date: Dec 2032 --> Jul 2033
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • Niktimvo (axatilimab-csfr)
    20d
    Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation (clinicaltrials.gov)
    P2, N=35, Recruiting, Stephen Shiao | Active, not recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Niktimvo (axatilimab-csfr)
    24d
    Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study (clinicaltrials.gov)
    P=N/A, N=500, Active, not recruiting, West China Hospital
    New trial
    |
    SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2)
    |
    Sulanda (surufatinib)
    24d
    Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial (clinicaltrials.gov)
    P2, N=72, Not yet recruiting, Mayo Clinic | Trial completion date: Jan 2033 --> Jun 2033 | Initiation date: Jan 2026 --> Jun 2026 | Trial primary completion date: Jan 2028 --> Jun 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    cyclophosphamide • Niktimvo (axatilimab-csfr)